Moving toward tuberculosis elimination: Implementation of statewide targeted tuberculin testing in Tennessee

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 3, 2012, Pages 273-279

  Cain, Kevin P ^a   Garman, Katie N ^b   Laserson, Kayla F ^a   Ferrousier Davis, Odile P ^a,c   Miranda, Abraham G ^a,d   Wells, Charles D ^a,e   Haley, Connie A ^a,b,f  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b TENNESSEE DEPARTMENT OF HEALTH   (United States)

^c INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^d U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^e Otsuka Pharmaceutical Development and Commercialization   (United States)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Emigrants and immigrants; Latent tuberculosis; Mass screening

Indexed keywords

ISONIAZID; RIFAMPICIN;

ARTICLE; CONTROLLED STUDY; FEASIBILITY STUDY; HUMAN; INFECTION PREVENTION; INFECTION RATE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; UNITED STATES;

COST-BENEFIT ANALYSIS; EMIGRATION AND IMMIGRATION; FEASIBILITY STUDIES; HUMANS; LATENT TUBERCULOSIS; MASS SCREENING; RISK FACTORS; TENNESSEE; TUBERCULIN TEST; TUBERCULOSIS;

EID: 84864510467     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201111-2076OC     Document Type: Article

References (68)

1. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2010. Atlanta, GA: US Department of Health and Human Services, CDC; 2011.
2. Centers for Disease Control and Prevention. Trends in tuberculosis-United States, 2010. MMWR Morb Mortal Wkly Rep 2011;60:333-337.
3. Chin DP, DeRiemer K, Small PM, de Leon AP, Steinhart R, Schecter GF, Daley CL, Moss AR, Paz EA, Jasmer RM, et al. Differences in contributing factors to tuberculosis incidence in US-born and foreign-born persons. Am J Respir Crit Care Med 1998;158:1797-1803. (Pubitemid 29008817)
4. Geng E, Kreiswirth B, Driver C, Li J, Burzynski J, DellaLatta P, LaPaz A, Schluger NW. Changes in the transmission of tuberculosis in New York City from 1990 to 1999. N Engl J Med 2002;346:1453-1458. (Pubitemid 34755713)
5. Jasmer RM, Hahn JA, Small PM, Daley CL, Behr MA, Moss AR, Creasman JM, Schecter GF, Paz EA, Hopewell PC. A molecular epidemiologic analysis of tuberculosis trends in San Francisco, 1991-1997. Ann Intern Med 1999;130:971-978. (Pubitemid 29283987)
6. Ricks PM, Cain KP, Oeltmann JE, Kammerer JS, Moonan PK. Estimating the burden of tuberculosis among foreign-born persons acquired prior to entering the US, 2005-2009. PLoS ONE 2011;6:e27405.
7. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000;49:1-51.
8. Institute of Medicine. Ending neglect: the elimination of tuberculosis in the United States. Washington, DC: National Academy Press; 2000.
9. Cain KP, Haley CA, Armstrong LR, Garman KN, Wells CD, Iademarco MF, Castro KG, Laserson KF. Tuberculosis among foreign-born persons in the United States: achieving tuberculosis elimination. Am J Respir Crit Care Med 2007;175:75-79. (Pubitemid 46105312)
10. Cain KP, Mac Kenzie WR. Editorial commentary: overcoming the limits of tuberculosis prevention among foreign-born individuals: next steps toward eliminating tuberculosis. Clin Infect Dis 2008;46:107-109. (Pubitemid 351263569)
11. Taylor Z, Nolan CM, Blumberg HM. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep 2005;54:1-81.
12. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003;168:443-447. (Pubitemid 37046873)
13. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-1018. (Pubitemid 29143893)
14. Mandalakas AM, Menzies D. Is screening immigrants for latent tuberculosis cost-effective? Lancet Infect Dis 2011;11:418-419.
15. Pareek M, Watson JP, Ormerod LP, Kon OM, Woltmann G, White PJ, Abubakar I, Lalvani A. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and costeffectiveness analysis. Lancet Infect Dis 2011;11:435-444.
16. Khan K, Muennig P, Behta M, Zivin JG. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med 2002;347:1850-1859. (Pubitemid 35417777)
17. Rose DN, Schechter CB, Fahs MC, Silver AL. Tuberculosis prevention: cost-effectiveness analysis of isoniazid chemoprophylaxis. Am J Prev Med 1988;4:102-109.
18. Rose DN, Schechter CB, Silver AL. The age threshold for isoniazid chemoprophylaxis. A decision analysis for low-risk tuberculin reactors. JAMA 1986;256:2709-2713. (Pubitemid 17178087)
19. Salpeter SR, Sanders GD, Salpeter EE, Owens DK. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med 1997;127:1051-1061. (Pubitemid 28012074)
20. Schechter CB, Rose DN, Fahs MC, Silver AL. Tuberculin screening: cost-effectiveness analysis of various testing schedules. Am J Prev Med 1990;6:167-175. (Pubitemid 20282924)
21. Snider DE Jr, Caras GJ, Koplan JP. Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. JAMA 1986;255:1579-1583. (Pubitemid 16167478)
22. Advisory Council for the Elimination of Tuberculosis (ACET). Tuberculosis elimination revisited: obstacles, opportunities, and a renewed commitment. MMWR Recomm Rep 1999;48:1-13.
23. Cain KP, Benoit SR, Winston CA, Mac Kenzie WR. Tuberculosis among foreign-born persons in the United States. JAMA 2008;300: 405-412. (Pubitemid 352040252)
24. Lobato MN, Wang YC, Becerra JE, Simone PM, Castro KG. Improved program activities are associated with decreasing tuberculosis incidence in the United States. Public Health Rep 2006;121:108-115.
25. Sterling TR, Bethel J, Goldberg S, Weinfurter P, Yun L, Horsburgh CR. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med 2006;173:927-931.
26. Haley CA. Treatment of latent tuberculosis infection. In: Schlossberg D, editor. Tuberculosis and nontuberculous mycobacterial infections, 6th ed. Washington, DC: ASM Press; 2011. pp. 83-106.
27. Hirsch-Moverman Y, Daftary A, Franks J, Colson PW. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis 2008;12:1235-1254.
28. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004;350:2060-2067.
29. Horsburgh CR Jr, Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, Hughes S, Shrestha-Kuwahara R, Sterling TR, Wall K, et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2010;137:401-409.
30. LoBue P, Menzies D. Treatment of latent tuberculosis infection: an update. Respirology 2010;15:603-622.
31. Tennessee Department of Health. Epidemiological profile of reported tuberculosis in Tennessee, 2001. Nashville, TN: Tennessee Department of Health, Communicable and Environmental Disease Services; 2001.
32. Haley CA, Cain KP, Yu C, Garman KF, Wells CD, Laserson KF. Risk-based screening for latent tuberculosis infection. South Med J 2008; 101:142-149.
33. Huebner R, Schein M, Bass J Jr. The tuberculin skin test. Clin Infect Dis 1993;17:969-975.
34. Iseman MD. A clinician's guide to tuberculosis. Baltimore, MD: Lippincott Williams & Wilkins. 2000.
35. Cain KP, Garman KF, Laserson KF, Wells CD, Haley CA. Targeted tuberculin testing: successful implementation of CDC/ATS guidelines for a statewide public health program [abstract]. Presented at the American Thoracic Society International Conference. May 20-25, 2005, San Diego, CA.
36. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992;145:36-41.
37. Polesky A, Farber HW, Gottlieb DJ, Park H, Levinson S, O'Connell JJ, McInnis B, Nieves RL, Bernardo J. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med 1996; 154:1473-1477. (Pubitemid 26391200)
38. Reichman LB, Lardizabal A, Hayden CH. Considering the role of four months of rifampin in the treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2004;170:832-835. (Pubitemid 39346476)
39. Villarino ME, Ridzon R, Weismuller PC, Elcock M, Maxwell RM, Meador J, Smith PJ, Carson ML, Geiter LJ. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med 1997;155:1735-1738. (Pubitemid 27216686)
40. Landry J, Menzies D. Preventive chemotherapy. Where has it got us? Where to go next? Int J Tuberc Lung Dis 2008;12:1352-1364.
41. Guh A, Sosa L, Hadler JL, Lobato MN. Missed opportunities to prevent tuberculosis in foreign-born persons, Connecticut, 2005-2008. Int J Tuberc Lung Dis 2011;15:1044-1049.
42. Linas BP, Wong AY, Freedberg KA, Horsburgh CR Jr. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med 2011;184:590-601.
43. Migration Policy Institute. Migration Policy Institute Data Hub; c2012 [accessed 2012May 29]. Available from: http://www.migrationinformation.org/ datahub/state.cfm?ID=TN
44. Colson PW, Franks J, Sondengam R, Hirsch-Moverman Y, El-Sadr W. Tuberculosis knowledge, attitudes, and beliefs in foreign-born and US-born patients with latent tuberculosis infection. J Immigr Minor Health 12:859-866.
45. Shieh FK, Snyder G, Robert Horsburgh C, Bernardo J, Murphy C, Saukkonen JJ. Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Respir Crit Care Med 2006;174:717-721. (Pubitemid 44395341)
46. Bock NN, Metzger BS, Tapia JR, Blumberg HM. A tuberculin screening and isoniazid preventive therapy program in an inner-city population. Am J Respir Crit Care Med 1999;159:295-300. (Pubitemid 29036538)
47. Lobato MN, Reves RR, Jasmer RM, Grabau JC, Bock NN, Shang N. Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons. Chest 2005;127:1296-1303. (Pubitemid 46224294)
48. Nolan CM. Community-wide implementation of targeted testing for and treatment of latent tuberculosis infection. Clin Infect Dis 1999;29:880-887. (Pubitemid 30256386)
49. Tulsky JP, Pilote L, Hahn JA, Zolopa AJ, Burke M, Chesney M, Moss AR. Adherence to isoniazid prophylaxis in the homeless: a randomized controlled trial. Arch Intern Med 2000;160:697-702. (Pubitemid 30140420)
50. Tulsky JP, White MC, Dawson C, Hoynes TM, Goldenson J, Schecter G. Screening for tuberculosis in jail and clinic follow-up after release. Am J Public Health 1998;88:223-226. (Pubitemid 28134080)
51. White MC, Tulsky JP, Goldenson J, Portillo CJ, Kawamura M, Menendez E. Randomized controlled trial of interventions to improve follow-up for latent tuberculosis infection after release from jail. Arch Intern Med 2002;162:1044-1050. (Pubitemid 34492535)
52. White MC, Tulsky JP, Menendez E, Goldenson J, Kawamura LM. Incidence of TB in inmates with latent TB infection: 5-year follow-up. Am J Prev Med 2005;29:295-301. (Pubitemid 41483535)
53. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, et al.; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365:2155-2166.
54. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006;130:1712-1717. (Pubitemid 46033423)
55. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004;170:445-449. (Pubitemid 39214621)
56. Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, Bur S, Walsh T, Karney W, Milman J, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006;166:1863-1870.
57. Ziakas PD, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis 2009;49:1883-1889.
58. Charles P. Felton National Tuberculosis Center. Adherence to treatment for latent tuberculosis infection: a manual for health care providers. New York: Charles P. Felton National Tuberculosis Center; 2005.
59. Parsyan AE, Saukkonen J, Barry MA, Sharnprapai S, Horsburgh CR Jr. Predictors of failure to complete treatment for latent tuberculosis infection. J Infect 2007;54:262-266. (Pubitemid 46238167)
60. Marks S. Tuberculosis evidence-statement: screening. In: Campbell K, Lanza A, Dixon R, Chattopadhyay S, Molinari N, Finch R, editors. A purchaser's guide to clinical preventive services: moving science into coverage. Washington, DC: National Business Group on Health; c2006 [accessed 2012 May 29]. pp. 427-435. Available from: http://www.businessgrouphealth.org/benefitstopics/ topics/purchasers/fullguide.pdf
61. Schwartzman K, Oxlade O, Barr RG, Grimard F, Acosta I, Baez J, Ferreira E, Melgen RE, Morose W, Salgado AC, et al. Domestic returns from investment in the control of tuberculosis in other countries. N Engl J Med 2005;353:1008-1020. (Pubitemid 41262335)
62. Aspler A, Long R, Trajman A, Dion MJ, Khan K, Schwartzman K, Menzies D. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax 2010;65:582-587.
63. Holland DP, Sanders GD, Hamilton CD, Stout JE. Costs and costeffectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med 2009;179:1055-1060.
64. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection - United States. MMWR Recomm Rep 2010;59:1-25.
65. Nienhaus A, Schablon A, Costa JT, Diel R. Systematic review of cost and cost-effectiveness of different TB-screening strategies. BMC Health Serv Res 2011;11:247.
66. Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis 2007;11:16-26. (Pubitemid 46101841)
67. American Community Survey Fact Finder. U.S. Census Bureau. American Fact Finder [accessed 2012 May 29]. Available from: http://factfinder2.census.gov
68. Bennett DE, Courval JM, Onorato I, Agerton T, Gibson JD, Lambert L, McQuillan GM, Lewis B, Navin TR, Castro KG. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. Am J Respir Crit Care Med 2008;177:348-355. (Pubitemid 351198380)